ArticleBMC public health2025
Disease burden and cause-eliminated life expectancy of digestive system cancers in southern China: a cross-sectional study originated from population-based cancer registration data in Guangdong Province.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundTo analyze the epidemiological characteristics and disease burden of digestive system cancer in Guangdong in 2019, and to provide evidence for prevention and treatment of digestive system cancer.
methodsBoth incidence and mortality data of the five digestive system cancers (esophageal cancer, stomach cancer, colorectal cancer, liver cancer and pancreatic cancer ) used in calculations originated from the cancer registration system of Guangdong Province. Crude incidence rate, mortality rate, age-standardized incidence and mortality rate, 35–64 year-old truncated incidence and mortality rate, 0–64 year-old cumulative incidence and mortality rate, disability adjusted life years (DALY), and cause-eliminated life expectancy were used to estimate the disease burden due to digestive system cancers in Guangdong province in this study. The life expectancy and the cause-eliminated life expectancy were calculated using an abridged life table method in this study. The standard population adopted in this study was the Segi’s world standard population.
resultsIn 2019, the crude incidence rates and crude mortality rates of digestive system cancers were 82.30/100,000 and 56.53/100,000 respectively in Guangdong Province. The age-standardized incidence rates and age-standardized mortality rates were 59.61/100,000 and 37.27/100,000, respectively. The total DALY and DALY rate of digestive system cancers in Guangdong Province were 1,681,089 person-years and 1,459.42/100,000. After eliminating causes of death from digestive system cancers, the life expectancy increased by 0.83 years, from 84.10 years to 84.93 years in Guangdong Province. In the disease burden of digestive system cancer, the disease burden is higher in males than in females and higher in rural areas compared to urban areas. Among these, colorectal cancer has the highest incidence, liver cancer exhibited the highest mortality, disease burden, and the most significant impact on life expectancy.
conclusionsDigestive system cancers exhibited a heavy disease burden in Guangdong Province. There were discernible gender and regional disparities in the incidence, mortality, and disease burden associated with five digestive system cancers. Liver cancer and colorectal cancer emerged as the predominant malignancies contributing to the disease burden in Guangdong Province. The vast majority of DALYs were due to YLL, indicating the need to focus resources on disease prevention and early detection. Guangdong Province should implement targeted interventions against modifiable risk factors for colorectal and liver cancers among high-risk populations and in high-incidence regions, thereby reducing the disease burden in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.